Strides Pharma Science Ltd on Monday said it has successfully completed the EU GMP inspection carried out by the National Institute of Pharmacy and Nutrition (OGYÉI), Hungary at its Puducherry facility.
Reacting to the developments, Shares of Strides Pharma Science Ltd clocked to an intraday high at s. 787, up by over 2.5 percent from the previous closing on the NSE.
According to the company, the inspection was carried out on April 28, 2021 and it has now received the renewed GMP (Good Manufacturing Practices) certificate thereby confirming the successful closure of the inspection, Strides Pharma Science said in a regulatory filing. The company had in August 2020, also announced the successful completion of the UK MHRA inspection at the site, it added.
''The Puducherry facility caters to the US, other regulated markets and institutional businesses and has capabilities to produce finished dosage formulation products across multiple dosage formats,'' the company said.
The Bengaluru-headquartered firm mainly operates in the regulated markets and has an 'in Africa for Africa' strategy along with an institutional business to service donor-funded markets. Its global manufacturing sites are located in Chennai, Puducherry and two units in Bengaluru, Singapore, Milan in Italy, Nairobi in Kenya and Florida in the US.
Adani Ports aims to become world’s top port operator by 2030: Reports
Petrol and diesel prices hiked again, know today's price
Covid-hit FY 2020-21: Indian Railways improves operating ratio to 97.45 pc